Association study of the excitatory amino acid transporter 2 (EAAT2) and glycine transporter 1 (GlyT1) gene polymorphism with schizophrenia in a Polish population

References

• Sullivan PF, Kendler KS, Neale MC. Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiat. 2003;60:1187–1192. doi:10.1001/archpsyc.60.12.1187
   PubMed Web of Science ®Google Scholar
• Stahl SM. Essential Psychopharmacology. 3rd ed. New York: Cambridge University Press; 2008.
   Google Scholar
• Fairman WA, Amara SG. Functional diversity of excitatory amino acid transporters: ion channel and transport modes. Am J Physiol. 1999;277:481–486. doi:10.1152/ajpheart.1999.277.5.H2002
   Web of Science ®Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308. doi:10.1176/ajp.148.10.1301
   PubMed Web of Science ®Google Scholar
• Krystal JH, Perry EB Jr, Gueorguieva R, et al. Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry. 2005;62:985–994. doi:10.1001/archpsyc.62.9.985
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214. doi:10.1001/archpsyc.1994.03950030035004
   PubMed Web of Science ®Google Scholar
• Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA. Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology. 2001;25:455–467. doi:10.1016/S0893-133X(01)00243-3
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Adams B, Verma A, Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci. 1997;17:2921–2927. doi:10.1523/JNEUROSCI.17-08-02921.1997
   PubMed Web of Science ®Google Scholar
• Stefansson H, Ophoff RA, Steinberg S, et al. Common variants conferring risk of schizophrenia. Nature. 2009;460(7256):744–747. doi:10.1038/nature08186
   PubMed Web of Science ®Google Scholar
• Ripke S, Sanders AR, Kendler KS, et al. Genome-wide association study identifies five new schizophrenia loci. Nat Genet. 2011;43:969–976. doi:10.1038/ng.940
   PubMed Web of Science ®Google Scholar
• Schijven D, Kofink D, Tragante V, et al. Comprehensive pathway analyses of schizophrenia risk loci point to dysfunctional postsynaptic signaling. Schizophr Res. 2018;199:195–202. doi:10.1016/j.schres.2018.03.032
   Web of Science ®Google Scholar
• Ripke S, Neale BM, Corvin A, et al. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421–427. doi:10.1038/nature13595
   PubMed Web of Science ®Google Scholar
• Ohi K, Hashimoto R, Ikeda M, et al. Glutamate networks implicate cognitive impairments in schizophrenia: genome-wide association studies of 52 cognitive phenotypes. Schizophr Bull. 2015;41(4):909–918. doi:10.1093/schbul/sbu171
   Web of Science ®Google Scholar
• Tarabeux J, Kebir O, Gauthier J, et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry. 2011;1:e55. doi:10.1038/tp.2011.52
   Web of Science ®Google Scholar
• Van Horn MR, Sild M, Ruthazer ES. D-serine as a gliotrans- mitter and its roles in brain development and disease. Front Cell Neurosci. 2013;7:39.
   PubMed Web of Science ®Google Scholar
• Rose EM, Koo JC, Antflick JE, Ahmed SM, Angers S, Hampson DR. Glutamate transporter coupling to Na, K-ATPase. J Neurosci. 2009;29(25):8143–8155. doi:10.1523/JNEUROSCI.1081-09.2009
   Web of Science ®Google Scholar
• Danbolt NC. Glutamate uptake. Prog Neurobiol. 2001;65(1):1–105. doi:10.1016/S0301-0082(00)00067-8
   PubMed Web of Science ®Google Scholar
• Nakagawa T, Kaneko S. SLC1 glutamate transporters and diseases: psychiatric diseases and pathological pain. Curr Mol Pharmacol. 2013;6(2):66–73. doi:10.2174/18744672113069990033
   Google Scholar
• Arriza JL, Eliasof S, Kavanaugh MP, Amara SG. Excitatory aminoacid transporter 5, a retinal glutamate transporter coupled to a chloride conductance. Proc Natl Acad Sci USA. 1997;94:4155–4160. doi:10.1073/pnas.94.8.4155
   PubMed Web of Science ®Google Scholar
• Lauriat TL, Dracheva S, Chin B, Schmeidler J, McInnes LA, Haroutunian V. Quantitative analysis of glutamate transporter mRNA expression in prefrontal and primary visual cortex in normal and schizophrenic brain. Neuroscience. 2006;(137):843–851. doi:10.1016/j.neuroscience.2005.10.003.
   Web of Science ®Google Scholar
• Sheldon AL, Robinson MB. The role of glutamate transporters in neurodegenerative diseases and potential opportunities for intervention. Neurochem Int. 2007;51:333–355. doi:10.1016/j.neuint.2007.03.012
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Martin L, Levey AI, et al. Localization of neuronal and glial glutamate transporters. Neuron. 1994;13:713–725. doi:10.1016/0896-6273(94)90038-8
   PubMed Web of Science ®Google Scholar
• Domercq M, Etxebarria E, Perez-Samartin A, Matute C. Excitotoxic oligodendrocyte death and axonal damage induced by glutamate transporter inhibition. Glia. 2005;52:36–46. doi:10.1002/glia.20221
   Web of Science ®Google Scholar
• Bauer D, Haroutunian V, Meador-Woodruff JH, et al. Abnormal glycosylation of EAAT1 and EAAT2 in prefrontal cortex of elderly patients with schizophrenia. Schizophr Res. 2010;117:92–98. doi:10.1016/j.schres.2009.07.025
   Web of Science ®Google Scholar
• Shan D, Lucas EK, Drummond JB, et al. Abnormal expression of glutamate transporters in temporal lobe areas in elderly patients with schizophrenia. Schizophr Res. 2013;144:1–8. doi:10.1016/j.schres.2012.12.019
   Web of Science ®Google Scholar
• Rao JS, Kellom M, Reese EA, et al. Dysregulated glutamate and dopamine transporters in postmortem frontal cortex from bipolar and schizophrenic patients. J Affect Disord. 2012;136:63–71. doi:10.1016/j.jad.2011.08.017
   PubMed Web of Science ®Google Scholar
• Ohnuma T, Tessler S, Arai H, Faull RL, McKenna PJ, Emson PC. Gene expression of metabotropic glutamate receptor 5 and excitatory amino acid transporter 2 in the schizophrenic hippocampus. Brain Res Mol Brain Res. 2000;85(1–2):24–31. doi:10.1016/S0169-328X(00)00222-9
   PubMedGoogle Scholar
• Meyer T, Ludolph AC, Morkel M, Hagemeier C, Speer A. Genomic organization of the human excitatory amino acid transporter gene GLT-1. Neuroreport. 1997;8:775–777. doi:10.1097/00001756-199702100-00039
   PubMed Web of Science ®Google Scholar
• Mallolas J, Hurtado O, Castellanos M, et al. A polymorphism in the EAAT2 promoter is associated with higher glutamate concentrations and higher frequency of progressing stroke. J Exp Med. 2006;203(3):711–717. doi:10.1084/jem.20051979
   PubMed Web of Science ®Google Scholar
• Zafra F, Gomeza J, Olivares L, Aragón C, Giménez C. Regional distribution and developmental variation of the glycine transporters GLYT1 and GLYT2 in the rat CNS. Eur J Neurosci. 1995;7(6):1342–1352. doi:10.1111/j.1460-9568.1995.tb01125.x
   PubMed Web of Science ®Google Scholar
• Danysz W, Parsons AC. Glycine and N-methyl-D-aspartate receptors: physiological significance and possible therapeutic applications. Pharmacol Rev. 1998;50:597–664.
   PubMed Web of Science ®Google Scholar
• Waziri R, Baruah S, Sherman AD. Abnormal serine-glycine metabolism in the brains of schizophrenics. Schizophr Res. 1993;8(3):233–243. doi:10.1016/0920-9964(93)90021-A
   Web of Science ®Google Scholar
• Heresco-Levy U, Javitt DC. Comparative effects of glycine and D-cycloserine on persistent negative symptoms in schizophrenia: a retrospective analysis. Schizophr Res. 2004;66(2–3):89–96. doi:10.1016/S0920-9964(03)00129-4
   PubMed Web of Science ®Google Scholar
• Williams JB, Mallorga PJ, Conn PJ, Pettibone DJ, Sur C. Effects of typical and atypical antipsychotics on human glycine transporters. Schizophr Res. 2004;71(1):103–112. doi:10.1016/j.schres.2004.01.013
   Web of Science ®Google Scholar
• Tsai G, Lane HY, Yang P, Chong MY, Lange N. Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia. Biol Psychiatry. 2004;55:452–456. doi:10.1016/j.biopsych.2003.09.012
   PubMed Web of Science ®Google Scholar
• Nelson N. The family of Na+/Cl- neurotransmitter transporters. J Neurochem. 1998;71(5):1785–1803. doi:10.1046/j.1471-4159.1998.71051785.x
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• van der Gaag M, Hoffman T, Remijsen M, et al. The five-factor model of the positive and negative syndrome scale II: a ten-fold cross-validation of a revised model. Schizophr Res. 2006;85:280–287. doi:10.1016/j.schres.2006.03.021
   PubMed Web of Science ®Google Scholar
• Dumais A, Lesage AD, Lalovic A, et al. Is violent method of suicide a behavioral marker of lifetime aggression? Am J Psychiatry. 2005;162(7):1375–1378. doi:10.1176/appi.ajp.162.7.1375
   Web of Science ®Google Scholar
• Morita Y, Ujike H, Tanaka Y, et al. The glycine transporter 1 gene (GLYT1) is associated with methamphetamine-use disorder. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(1):54–58. doi:10.1002/ajmg.b.30565
   Web of Science ®Google Scholar
• Matsumoto Y, Suzuki A, Ishii G, Oshino S, Otani K, Goto K. The −181 A/C polymorphism in the excitatory amino acid transporter-2 gene promoter affects the personality trait of reward dependence in healthy subjects. Neurosci Lett. 2007;427(2):99–102. doi:10.1016/j.neulet.2007.09.015
   Web of Science ®Google Scholar
• Poletti S, Radaelli D, Bosia M, et al. Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. Eur Psychiatry. 2014;29(4):219–225. doi:10.1016/j.eurpsy.2013.07.003
   Web of Science ®Google Scholar
• NCBI. Reference SNP (refSNP) Cluster Report: rs4354668. Available from: https://www.ncbi.nlm.nih.gov/projects/SNP/snp_ref.cgi?rs=4354668. Accessed July 11, 2018.
   Google Scholar
• Zhang B, Guan F, Chen G, et al. Common variants in SLC1A2 and schizophrenia: association and cognitive function in patients with schizophrenia and healthy individuals. Schizophr Res. 2015;169(1–3):128–134. doi:10.1016/j.schres.2015.10.012
   Web of Science ®Google Scholar
• Deng X, Shibata H, Ninomiya H, et al. Association study of polymorphisms in the excitatory amino acid transporter 2 gene (SLC1A2) with schizophrenia. BMC Psychiatry. 2004;4:21. doi:10.1186/1471-244X-4-21
   PubMed Web of Science ®Google Scholar
• Nagai Y, Ohnuma T, Karibe J, et al. No genetic association between the SLC1A2 gene and Japanese patients with schizophrenia. Neurosci Lett. 2009;463(3):223–227. doi:10.1016/j.neulet.2009.07.092
   Web of Science ®Google Scholar
• Deng X, Sagata N, Takeuchi N, et al. Association study of polymorphisms in the neutral amino acid transporter genes SLC1A4, SLC1A5 and the glycine transporter genes SLC6A5, SLC6A9 with schizophrenia. BMC Psychiatry. 2008;8:58. doi:10.1186/1471-244X-8-58
   Web of Science ®Google Scholar
• Tsai SJ, Cheng CY, Hong CJ, Liao DL, Liou YJ. Polymorphisms in glycine transporter with schizophrenia. Neuropsychopharmacol Hung. 2006;8(1):17–21.
   Google Scholar
• Kang WS, Park HJ, Park JK, Cho AR, Kim JW. Association study between solute carrier family 6, member 9 (SLC6A9) gene and schizophrenia in Korean population (abstract). 10th World Congress of Biological Psychiatry. 2011. doi: 10.3284/wfsbp.2011.1
   Google Scholar
• Abel KM, Drake R, Goldstein JM. Sex differences in schizophrenia. Int Rev Psychiatry. 2010;22(5):417–428. doi:10.3109/09540261.2010.515205
   PubMed Web of Science ®Google Scholar
• Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review schizophrenia research and treatment. Schizophr Res Treat. 2012;2012:916198.
   PubMedGoogle Scholar
• Qin W, Liu C, Sodhi M, Lu H. Meta-analysis of sex differences in gene expression in schizophrenia. BMC Syst Biol. 2016;10(1):100–106. doi:10.1186/s12918-016-0304-1
   Web of Science ®Google Scholar
• Spangaro M, Bosia M, Zanoletti A, et al. Cognitive dysfunction and glutamate reuptake: effect of EAAT2 polymorphism in schizophrenia. Neurosci Lett. 2012;522(2):151–155. doi:10.1016/j.neulet.2012.06.030
   Web of Science ®Google Scholar
• Spangaro M, Bosia M, Zanoletti A, et al. Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics. 2014;15(7):925–932. doi:10.2217/pgs.14.42
   Web of Science ®Google Scholar
• Dallaspezia S, Poletti S, Lorenzi C, et al. Influence of an interaction between lithium salts and a functional polymorphism in SLC1A2 on the history of illness in bipolar disorder. Mol Diagn Ther. 2012;16(5):303–309. doi:10.1007/s40291-012-0004-5
   Web of Science ®Google Scholar
• Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry. 2008;64(2):89–97. doi:10.1016/j.biopsych.2007.11.010
   Web of Science ®Google Scholar
• Kim K, Lee SG, Kegelman TP, et al. Role of excitatory amino acid transporter-2 (EAAT2) and glutamate in neurodegeneration: opportunities for developing novel therapeutics. J Cell Physiol. 2011;226(10):2484–2493. doi:10.1002/jcp.22609
   PubMed Web of Science ®Google Scholar
• Łoza B. Nowe wymiary leczenia schizofrenii. Psychiatria. 2005;1:1–8.
   Google Scholar
• Wallwork RS, Fortgang R, Hashimoto R, Weinberger DR, Dickinson D. Searching for a consensus five-factor model of the positive and negative syndrome scale for schizophrenia. Schizophr Res. 2012;137(1–3):246–250. doi:10.1016/j.schres.2012.01.031
   PubMed Web of Science ®Google Scholar
• Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24:81–90. doi:10.1177/1359786810385490
   PubMed Web of Science ®Google Scholar
• Kim SW, Kim SJ, Mun JW, et al. Psychosocial factors contributing to suicidal ideation in hospitalized schizophrenia patients in Korea. Psychiatry Invest. 2010;7(2):79–85. doi:10.4306/pi.2010.7.2.79
   Web of Science ®Google Scholar